Expression of Ki67 as detected by MIB-1 and its association with histopathological high-risk factors among patients with retinoblastoma tumour: a cross-sectional study
Abstract:ObjectivesThis study aims to investigate the expression of Ki67 in formalin-fixed paraffin-embedded tissue blocks from patients with a diagnosis of retinoblastoma tumour (RbT) as well as determining its association with histopathological high-risk factors (HHRFs).Methods and analysisRetrospectively, a total of 194 eyeball specimens from 163 children with RbT were reviewed at Muhimbili National Hospital between 2009 and 2013. Immunohistochemical expression of Ki67 using MIB-1 antibody (Abcam, batch ab93680, Cam… Show more
“…As expected, the proliferative activity (Ki-67) was high, notably in the outer proliferative rim for Y79 tumoroids. 33 Furthermore, the retinoblastoma tumoroids maintained both nuclear expression of early photoreceptor/cone marker orthodenticle homeobox 2 (OTX1-2) and cytoplasmic expression of late cone marker arrestin 3 (ARR3), which would define Y79 and WERI-Rb1 2D and 3D as subtype 2 retinoblastoma, following the classification of Liu et al 34 The Y79 tumoroids did not show significant differences in marker gene expression compared to 2D culture when analyzed at the RNA level (Figure S5). The only noticeable difference, although not significant, is a tendency to upregulate the pro-apoptotic factor BNIP3, linked to hypoxia, which might indicate the presence of a hypoxic region in the tumoroid model.…”
Section: Molecular Characterization Of Retinoblastoma Tumoroid Modelmentioning
confidence: 69%
“…As expected, the proliferative activity (Ki‐67) was high, notably in the outer proliferative rim for Y79 tumoroids. 33 Furthermore, the retinoblastoma tumoroids maintained both nuclear expression of early photoreceptor/cone marker orthodenticle homeobox 2 (OTX1‐2) and cytoplasmic expression of late cone marker arrestin 3 (ARR3), which would define Y79 and WERI‐Rb1 2D and 3D as subtype 2 retinoblastoma, following the classification of Liu et al 34 …”
Retinoblastoma is the most common pediatric eye cancer. It is currently treated with a limited number of drugs, adapted from other pediatric cancer treatments. Drug toxicity and relapse of the disease warrant new therapeutic strategies for these young patients. In this study, we developed a robust tumoroid‐based platform to test chemotherapeutic agents in combination with focal therapy (thermotherapy) – a treatment option widely used in clinical practice – in accordance with clinically relevant trial protocols. The model consists of matrix‐embedded tumoroids that retain retinoblastoma features and respond to repeated chemotherapeutic drug exposure similarly to advanced clinical cases. Moreover, the screening platform includes a diode laser (810 nm, 0.3 W) to selectively heat the tumoroids, combined with an on‐line system to monitor the intratumoral and surrounding temperatures. This allows the reproduction of the clinical settings of thermotherapy and combined chemothermotherapy treatments. When testing the two main drugs currently used in clinics to treat retinoblastoma in our model, we observed results similar to those clinically obtained, validating the utility of the model. This screening platform is the first system to accurately reproduce clinically relevant treatment methods and should lead to the identification of more efficient drugs to treat retinoblastoma.
“…As expected, the proliferative activity (Ki-67) was high, notably in the outer proliferative rim for Y79 tumoroids. 33 Furthermore, the retinoblastoma tumoroids maintained both nuclear expression of early photoreceptor/cone marker orthodenticle homeobox 2 (OTX1-2) and cytoplasmic expression of late cone marker arrestin 3 (ARR3), which would define Y79 and WERI-Rb1 2D and 3D as subtype 2 retinoblastoma, following the classification of Liu et al 34 The Y79 tumoroids did not show significant differences in marker gene expression compared to 2D culture when analyzed at the RNA level (Figure S5). The only noticeable difference, although not significant, is a tendency to upregulate the pro-apoptotic factor BNIP3, linked to hypoxia, which might indicate the presence of a hypoxic region in the tumoroid model.…”
Section: Molecular Characterization Of Retinoblastoma Tumoroid Modelmentioning
confidence: 69%
“…As expected, the proliferative activity (Ki‐67) was high, notably in the outer proliferative rim for Y79 tumoroids. 33 Furthermore, the retinoblastoma tumoroids maintained both nuclear expression of early photoreceptor/cone marker orthodenticle homeobox 2 (OTX1‐2) and cytoplasmic expression of late cone marker arrestin 3 (ARR3), which would define Y79 and WERI‐Rb1 2D and 3D as subtype 2 retinoblastoma, following the classification of Liu et al 34 …”
Retinoblastoma is the most common pediatric eye cancer. It is currently treated with a limited number of drugs, adapted from other pediatric cancer treatments. Drug toxicity and relapse of the disease warrant new therapeutic strategies for these young patients. In this study, we developed a robust tumoroid‐based platform to test chemotherapeutic agents in combination with focal therapy (thermotherapy) – a treatment option widely used in clinical practice – in accordance with clinically relevant trial protocols. The model consists of matrix‐embedded tumoroids that retain retinoblastoma features and respond to repeated chemotherapeutic drug exposure similarly to advanced clinical cases. Moreover, the screening platform includes a diode laser (810 nm, 0.3 W) to selectively heat the tumoroids, combined with an on‐line system to monitor the intratumoral and surrounding temperatures. This allows the reproduction of the clinical settings of thermotherapy and combined chemothermotherapy treatments. When testing the two main drugs currently used in clinics to treat retinoblastoma in our model, we observed results similar to those clinically obtained, validating the utility of the model. This screening platform is the first system to accurately reproduce clinically relevant treatment methods and should lead to the identification of more efficient drugs to treat retinoblastoma.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.